The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

With a capital T, that rhymes with P

Here’s a crazy idea: Let’s make a perfect heart health pill – a single pill that contains a statin drug to lower cholesterol, three different drugs (including an ACE inhibitor) to control blood pressure, a low dose of aspirin, and then throw in some folic acid to reduce homocysteine levels.

But wait – let’s get really crazy and say that this pill will not be just for people with heart problems, it will be for everyone over the age of 55. That’s right: everyone. You may not have high blood pressure and you may not have high LDL cholesterol, but as of your 55th birthday your doctor will probably recommend it anyway, just to be on the safe side.

Call it crazy, but what I’ve just described is being touted as a preventive treatment that, in the researchers’ own words, might have “a greater impact on the prevention of disease in the Western world than any other single intervention.”

When someone speaks a line like that with a straight face, you almost expect to hear a dozen trumpets g dat da-da DAAAA!

Collectors, take note

This newly proposed wonder drug for the heart is not only being seriously considered, but it’s also the subject of several articles and an editorial in the prestigious British Medical Journal (BMJ). In fact, in his introduction to the latest issue, BMJ editor Richard Smith suggests to readers that they hang on to their copies and consider them collectors items, stating that it’s been more than half a century since BMJ published something this important.

Cue those trumpets again.

Two professors in the Department of Preventive Medicine at the University of London – Dr. Nicholas Wald and Dr. Malcolm Law – are the masterminds behind this new treatment, which they call the Polypill. At this point the Polypill is only an idea, but Wald and Law are so taken with their imagined pill that they’ve filed both a trademark and a patent application for the proposed formulation.

“Proof” purchased

To determine the ingredients of their Polypill, Wald and Law first set a goal to address four cardiovascular risk factors: LDL cholesterol, high blood pressure, homocysteine levels, and platelet function. Then they went looking for studies that would support the use of ingredients that would: a) meet their risk factor reduction goals, b) work effectively, and c) have few side effects.

By incorporating the results of several “meta-analysis” research projects that examined a range of different studies, they say they’ve included the data of more than 750 trials, involving more than 400,000 subjects. And while that might sound impressive to the casual reader, we know the realities behind this type of research.

For instance, many of those trials would obviously involve prescription drugs. And because such studies are very expensive, they’re almost always funded by drug manufacturers. Research has also shown that sources of funding often influence the outcomes of studies. And when a study develops unwanted conclusions, the funding source often exercises the option to not report the study at all.

In other words – much of Wald and Law’s data supporting Polypill’s use of statins and high blood pressure medications is almost certainly working from a stacked deck. Nevertheless, W. and L. conclude that the Polypill could prevent 80 percent of heart attacks and stroke if taken by EVERYONE aged 55 and older, as well as everyone who already has cardiovascular disease.

When “acceptable” turns dangerous

And what about side effects? Wald and Law predict that the Polypill would be “acceptably safe.” Would that be kind of like the way the Titanic was “acceptably safe” from icebergs?

When you hear pharmaceutical researchers use the phrase “acceptably safe,” you know it’s time to run for cover.

In one of the other Polypill articles that appears in the current BMJ issue, Dr. Anthony Rodgers – the co-director of the Clinical Trials Research Unit at the University of Auckland, New Zealand – says that the projected number of patients that might discontinue use of the pill due to side effects would be only one or two per every 100. That doesn’t sound like much, unless you add up all the people over the age of 55 and all the people with cardiovascular disease. Then you’re talking about many thousands.

In addition, Dr. Rodgers states that the fatal side effects of the Polypill would be less than one in 10,000 users. Again, that may not sound like a huge death toll, but under the Wald/Law plan, tens of millions would pop the Polypill, resulting in hundreds or thousands of deaths each year. This bottom-line mentality tallies up data and concludes that saving the lives of 80 percent of all cardio patients at the expense of others is “acceptably safe.”

But what’s “acceptable” in the research lab is often entirely unacceptable out here in the real world. Especially in this case, simply because there are so many safer ways to address cardiovascular disease.

Feel-good spin

The projected numbers of Wald and Law are wildly optimistic. Not to mention completely wrongheaded. But don’t expect the mainstream to tread carefully as they run to embrace the Polypill.

In an Australian Broadcasting Corporation report, University of Queensland Professor Chris Del Mar (described as an expert in the field of “evidence-based” medicine) gushed about what he called the “whole population approach” of the Polypill, comparing it favorably to the fluoridation of public water supplies. In his estimation, the Polypill would be so safe that it should be available over-the-counter.

That’s great. While they’re at it, why not make it available in chewable flavors and sell it at grocery checkout counters? Or better yet, go ahead and add it to our water supply. Then they won’t have to worry about the non-compliant 55+ crowd ruining their press releases.

Professor Del Mar, Dr. Rodgers, Richard Smith and many others already seem to be signed, sealed, and delivered on the one-size-fits-all, magic heart pill. And I’m sure that everyone in this optimistic crowd will do all they can to help sell the Polypill to the general public as Wald and Law take their plan from proposal through development, clinical trials, and manufacturing.

So I’ll keep you posted, because we’re sure to hear more about this one. And if you have one of those “collectible” current issues of the BMJ, I think it is a good idea to save it. It may turn out to be one of the most laughably misguided predictions of the future in the past 50 years. Or one of the scariest.

No trumpets, please.

To Your Good Health,

Jenny Thompson
Health Sciences Institute

Sources:
“A Strategy to Reduce Cardiovascular Disease by More than 80%” Dr. Nicholas Wald and Dr. Malcolm Law, British Medical Journal; 326: 1419, 6/28/03, bmj.com
“A Cure for Cardiovascular Disease?” Anthony Rodgers, British Medical Journal; 326: 1407, 6/28/03, bmj.com
“Comparison of Methods to Identify Individuals at Increased Risk of Coronary Disease from the General Population” British Medical Journal; 326: 1436, 6/28/03, bmj.com
“The Most Important BMJ for 50 Years?” British Medical Journal; 326, 6/28/03, bmj.com
“Heart ‘Polypill’ Stirs Controversy” Associated Press, 6/26/03, msnbc.com
“Single Pill may Cut Heart Disease Risk by 80%” Australian Broadcasting Corporation Science Online and Reuters, 6/27/03, abc.net.au
“The World Today – Questions Raised over Polypill” Tanya Nolan, Australian Broadcasting Corporation, 6/27/03, abc.net.au

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.